With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC (MedTechDive)The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change at the FTC could lower M&A scrutiny.
Donald Trump’s victory in the U.S. presidential election Tuesday means change is coming for federal health agencies and the industries they regulate. It’s just not quite clear yet how dramatic that change might be.
Trump has pledged to “make America healthy again” and, in embracing Robert F. Kennedy Jr., a well-known critic of vaccines and pharmaceutical companies, has signaled such a campaign could feature unorthodox or disruptive ideas.
“I’m going to let him go wild on health,” Trump said in a campaign speech in New York last month. “I’m going to let him go wild on the food. I’m going to let him go wild on medicines.”
The potential for Kennedy to have a role overseeing or advising on healthcare policy is focusing the drug industry’s attention on how Trump might treat the Food and Drug Administration.
In his first term, Trump picked more traditional choices — Scott Gottlieb and then Stephen Hahn — as his FDA...
